c-kit Positive Pancreatic Stem Cell Isolation and Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective identification and isolation of pancreatic stem cells, which are crucial for treating pancreatic diseases and disorders, as existing technologies fail to recognize or isolate cells with stem cell characteristics from pancreatic tissues.
Innovation Solution
Discovery and utilization of c-kit positive cells in pancreatic tissues, which exhibit stem cell properties such as self-renewal, clonogenicity, and multipotentiality, allowing for their isolation and use in therapeutic applications to repair or regenerate pancreatic tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to identify pancreatic cells, then general pancreatic cell functions can be studied, but stem cell characteristics cannot be recognized or isolated
Solution Approach 1:
The patent uses immunohistochemical staining with specific antibodies (anti-c-kit, anti-Ngfr, anti-S100) that produce visible color changes to identify and distinguish pancreatic stem cells from other pancreatic cells. This staining technique enables precise visual identification of stem cells expressing specific markers, resolving the inability to recognize stem cell characteristics with conventional methods.
2Measurement precision
If pancreatic tissue is analyzed without specific staining, then tissue structure can be observed, but specific stem cell markers cannot be detected
Solution Approach 1:
The patent employs a multi-color immunohistochemical staining system where different antibodies are conjugated to different colored substrates (DAB for brown, AEC for red, NBT for blue). This allows simultaneous detection of multiple stem cell markers (c-kit, Ngfr, S100) in the same tissue section, achieving high marker detection sensitivity while providing a systematic approach to manage the procedural complexity.
3Reliability
If intensive insulin therapy is used to treat type 1 diabetes, then blood sugar control is improved, but quality of life and cost increase
Solution Approach 1:
The patent describes transplanting pancreatic stem cells or differentiated beta cells into diabetic patients, where the transplanted cells autonomously produce and secrete insulin in response to blood glucose levels. This restores the body's natural insulin regulation capability, eliminating the need for external insulin injections and frequent blood sugar monitoring, thereby improving quality of life while maintaining reliable blood sugar control.
4Adaptability or versatility
If pancreatic stem cells are not isolated, then therapeutic applications cannot be developed, but existing technologies fail to recognize or isolate these cells
Solution Approach 1:
The patent uses immunohistochemical staining with specific antibodies against stem cell markers (c-kit, Ngfr, S100) that produce distinct color changes to identify and isolate pancreatic stem cells. This precise identification method enables the development of therapeutic applications by allowing researchers to accurately select and culture pure populations of pancreatic stem cells for transplantation and regenerative medicine.
Data Source
AI summary
The disclosure relates to stem cells and their therapeutic use in the treatment and/or prevention of pancreatic diseases or disorders. Provided herein are compositions comprising c-kit positive pancreatic stem cells and methods of preparing and using c-kit positive pancreatic stem cells for the treatment and/or prevention of pancreatic diseases or disorders.